Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study

Arthritis Care and Research

Volumn 53, Issue 1, 2005, Pages 108-113

  Slot, Marjan C ^a,b   Links, Thera P ^b   Stegeman, Coen A ^b   Tervaert, Jan Willem Cohen ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA associated vasculitis; Drug induced; Hyperthyroidism; Propylthiouracil

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; LEUKOCYTE ELASTASE; MICROSOME ANTIBODY; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNOFLUORESCENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; SERUM; THYROID ADENOMA; THYROIDECTOMY; VASCULITIS;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTITHYROID AGENTS; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; THYROIDECTOMY; VASCULITIS;

EID: 13444310433     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20927     Document Type: Article

References (40)

1. Cohen Tervaert JW, Goldschmeding R, Elema JD, van der Giessen M, Huitema MG, van der Hem GK, et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990;37:799-806.
2. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512-23.
3. Velosa JA, Homburger HA, Holley KE. Prospective study of anti-neutrophil cytoplasmic autoantibody tests in the diagnosis of idiopathic necrotizing-crescentic glomerulonephritis and renal vasculitis. Mayo Clin Proc 1993;68:561-5.
4. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-33.
5. Cohen Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989;149:2461-5.
6. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87:4115-9.
7. Muller Kobold AC, van der Geld YM, Limburg PC, Cohen Tervaert JW, Kallenberg CG. Pathophysiology of ANCA-associated glomerulonephritis. Nephrol Dial Transplant 1999;14: 1366-75.
8. Heeringa P, Brouwer E, Cohen Tervaert JW, Weening JJ, Kallenberg CG. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int 1998;53:253-63.
9. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
10. Merkel P. Drugs associated with vasculitis. Curr Opin Rheumatol 1998;10:45-50.
11. Nassberger L, Johansson AC, Bjorck S, Sjoholm AG. Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment. J Intern Med 1991;229:261-5.
12. Almroth G, Enestrom S, Hed J, Samuelsson I, Sjostrom P. Autoantibodies to leucocyte antigens in hydralazine-associated nephritis. J Intern Med 1992;231:37-42.
13. Torffvit O, Thysell H, Nassberger L. Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis. Hum Exp Toxicol 1994;13:563-7.
14. Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. OJM 1995;88: 775-83.
15. Dolman KM, Gans RO, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993;342:651-2.
16. Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, Sinaiko A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 1994;124:986-8.
17. D'Cruz D, Chesser AM, Lightowler C, Comer M, Hurst MJ, Baker LR, et al. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheumatol 1995;34:1090-1.
18. Kitahara T, Hiromura K, Maezawa A, Ono K, Narabara N, Yano S, et al. Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA): review of literature. Clin Nephrol 1997;47:336-40.
19. Choi HK, Merkel PA, Cohen Tervaert JW, Black RM, McCluskey RT, Niles JL. Alternating antineutrophil cytoplasmic antibody specificity: drug-induced vasculitis in a patient with Wegener's granulomatosis. Arthritis Rheum 1999;42:384-8.
20. Hori Y, Arizono K, Hara S, Kawai R, Hara M, Yamada A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamazole therapy. Nephron 1996;74:734-5.
21. Kawachi Y, Nukaga H, Hoshino M, Iwata M, Otsuka F. ANCA-associated vasculitis and lupus-like syndrome caused by methimazole. Clin Exp Dermatol 1995;20:345-7.
22. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 2000;142:587-90.
23. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000;43:405-13.
24. Cohen Tervaert JW, Limburg PC, Elema JD, Huitema MG, Horst G, The TH, et al. Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med 1991;91:59-66.
25. Cohen Tervaert JW, Mulder L, Stegeman C, Elema J, Huitema M, The H, et al. Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis 1993;52:115-20.
26. McLachlan SM, Rapoport B. Autoimmune response to the thyroid in humans: thyroid peroxidase: the common autoantigenic denominator. Int Rev Immunol 2000;19:587-618.
27. Sera N, Ashizawa K, Ando T, Abe Y, Ide A, Usa T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000;10:595-9.
28. Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 2001;54:651-4.
29. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85: 4270-3.
30. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000;43:414-9.
31. Cohen Tervaert JW, Goldschmeding R, Elema JD, Limburg PC, van der Giessen M, Huitema MG, et al. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 1990;33:1264-72.
32. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993;36:365-71.
33. Cohen Tervaert JW, Huitema MG, Hene RJ, Sluiter WJ, The TH, van der Hem GK, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-11.
34. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995;25:380-9.
35. Locke IC, Leaker B, Cambridge G. A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions. Clin Exp Immunol 1999;115:369-76.
36. Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994;266:810-3.
37. Rubin RL, Kretz-Rommel A. Phagocyte-mediated oxidation in idiosyncratic adverse drug reactions. Curr Opin Hematol 2001;8:34-40.
38. Choi HK, Slot MC, Pan G, Weissbach CA, Niles JL, Merkel PA. Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum 2000;43:2488-92.
39. Haapala AM, Hyoty H, Parkkonen P, Mustonen J, Soppi E. Antibody reactivity against thyroid peroxidase and myeloperoxidase in autoimmune thyroiditis and systemic vasculitis. Scand J Immunol 1997;46:78-85.
40. Freire BA, Paula ID, Paula F, Kallenberg CG, Limburg PC, Queluz TT. Absence of cross-reactivity to myeloperoxidase of anti-thyroid microsomal antibodies in patients with autoimmune thyroid diseases. Am J Med Sci 2001;321:109-12.